AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced preliminary revenue results for the fourth quarter and full year ended Dec. 31, 2023. The Company expects the following: Total revenues of approximately $300 million in the fourth quarter of 2023, an increase of approximately 38% compared to $217 million in the fourth quarter of 2022. Total revenues of approximately $1.07 billion in 2023, an increase of approximately 30% compare ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, Jan. 9, 2024 at 3:45 p.m. PT (6:45 p.m. ET). Members of Natera’s management will deliver a presentation and host a Q&A with the investment community at the conference. A live webcast may be accessed through the investor relations section of the Natera website at investor.natera.co ...

red_moon_rise/E+ via Getty Images Executive Summary The journey to bring molecular non-invasive prenatal screening/testing 'NIPT' to mainstream healthcare standards hasn't been easy. The sector faced and overcame the challenges of proving the accuracy and reliability of this tech. Natera (NASDAQ:NTRA) offers an opportunity to capitalize on the considerable groundwork already laid as we enter an era of widespread acceptance for all pregnant women, regardless of age, leveraging the established trust and ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Molecular Oncology comparing the performance of mean tumor molecules per milliliter (MTM/mL) against mean variant allele frequency (mVAF) for measuring circulating tumor DNA (ctDNA), using Signatera™, Natera’s personalized and tumor-informed molecular residual disease (MRD) test. The full study can be found here. To date, mVAF and MTM/mL are the two main metrics th ...

Natera, Inc. (NASDAQ:NTRA) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - President of Clinical Diagnostics Alexey Aleshin - General Manager, Oncology & Chief Medical Officer Conference Call Participants Tejas Savant - Morgan Stanley Puneet Souda - Leerink Partners Catherine Schulte - Baird Rachel Vatnsdal - JPMorgan Dan Brennan - TD Cowen Operator Thank you for standing b ...

Investor presentation × × × × × × × × × × × × × × × × × Ｘ Ｘ x × × × × × × × Ｘ Ｘ × Ｘ Ｘ × X × × × × × × × These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: we face numerous uncertainties and challenges in achieving our financial projections and goals; we may be unable to further increase the use and adoption of our products through our direct sales efforts or through our laboratory partners; we have incurred ...

Table of Contents FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Commission file number: 001-37478 NATERA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 01-0894487 (State or O ...

Natera, Inc. × × × × × × × × × × × × × × × × × × Ⅹ Ｘ Ｘ Ｘ Ｘ Ｘ × × × × × × × × Ｘ Ｘ × × × × X X Safe harbor statement X × natera® Second Quarter 2023 Earnings Call August 3, 2023 × × × × × × × × × × Ⅹ Ｘ Ｘ Ｘ Ｘ Ｘ X X × × × × Ｘ Ｘ × × × x X X X × X X × × × × × Ｘ Ｘ × × × × × × × × × × Investor presentation × × × × 2 × × × × × These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: we face numerous uncertainties and chal ...

Natera, Inc. (NASDAQ:NTRA) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Michael Brophy – Chief Financial Officer Steve Chapman – Chief Executive Officer Solomon Moshkevich – General Manager-Oncology Conference Call Participants Tejas Savant – Morgan Stanley Catherine Schulte – Baird Rachel Vatnsdal – JPMorgan Puneet Souda – Leerink Partners Dan Brennan – TD Cowen David Westenberg – Piper Sandler Operator Welcome to Natera’s 2023 Second Quarter Financial Results Conference ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37478 NATERA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 01-0894487 (State or Other ...